HRTX - Why Heron Therapeutics Stock Is Getting Hammered Today
Shares of the small-cap biotech Heron Therapeutics (NASDAQ: HRTX) are down by a noteworthy 19.2% as of 2:48 p.m. ET Tuesday afternoon. The drugmaker's shares are cratering today in response to its disappointing 2021 fourth-quarter results.
What's the specific culprit behind this hefty sell-off? The lack of commercial momentum for Heron's non-opioid painkiller Zynrelef appears to be the biggest concern for shareholders today. Even though the drug was launched last July, it failed to bring in even $1 million in net revenue for the company in Q4 2021. The drug's unfavorable initial label simply hasn't allowed it to become a viable growth driver as of yet.
Image source: Getty Images.
For further details see:
Why Heron Therapeutics Stock Is Getting Hammered Today